BioNTech SE logo

BioNTech SENASDAQ: BNTX

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Germany

IPO:

10 October 2019

Next earnings report:

20 March 2025

Last dividends:

02 June 2022

Next dividends:

N/A
$24.86 B
-71%vs. 3y high
97%vs. sector
-vs. 3y high
-vs. sector
-86%vs. 3y high
42%vs. sector
-16%vs. 3y high
72%vs. sector

Price

regular market | 6 min ago
$103.71-$3.46(-3.23%)
$1.37 B$1.15 B
$1.37 B$217.87 M

Analysts recommendations

Institutional Ownership

BNTX Latest News

BioNTech Stock Has Been Hit Hard Since RFK Jr.'s Nomination. Why This Analyst Upgraded It.
barrons.com19 November 2024 Sentiment: POSITIVE

Evercore ISI analyst Cory Kasimov upgrades the German drugmaker's stock to Outperform from In Line.

BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock Up
zacks.com14 November 2024 Sentiment: POSITIVE

BioNTech inks a deal to acquire Biotheus and gain full global rights to a bispecific antibody, BNT327/PM8002, being studied for various oncology indications.

BioNTech Earns Upgrade From Goldman Sachs As Investment Thesis Shifts Toward Cancer Potential
benzinga.com09 November 2024 Sentiment: POSITIVE

Goldman Sachs has upgraded BioNTech SE BNTX, citing the company's BNT327, an immuno-oncology asset in clinical development across multiple solid tumors.

BioNTech Q3 Earnings Review: Good Quarter, Strong Promise -- But Still A Hold
seekingalpha.com06 November 2024 Sentiment: POSITIVE

BioNTech SE's stock saw a spike in September due to positive data from Summit Therapeutics' ivonescimab, which has a similar mechanism to BioNTech's BNT327. BioNTech's Q3 earnings showed improved revenues and profit, largely driven by its COVID-19 vaccine, Comirnaty, which remains a significant revenue source. Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a “Hold” rating.

BioNTech SE (BNTX) Q3 2024 Earnings Call Transcript
seekingalpha.com04 November 2024 Sentiment: POSITIVE

BioNTech SE (NASDAQ:BNTX ) Q3 2024 Earnings Conference Call November 4, 2024 8:00 AM ET Company Participants Michael Horowicz - Director, Investor Relations Ugur Sahin - Chief Executive Officer & Co-Founder Özlem Türeci - Chief Medical Officer & Co-Founder Jens Holstein - Chief Financial Officer Ryan Richardson - Chief Strategy Officer Conference Call Participants Tazeen Ahmad - Bank of America Securities Daina Graybosch - Leerink Partners Suzanne van Voorthuizen - VLK Terence Flynn - Morgan Stanley Yaron Werber - TD Cowen Jessica Fye - JPMorgan Chase Cory Kasimov - Evercore ISI Luke Shumway - BMO Capital Markets Ellie Merle - UBS Yifeng Liu - HSBC Bank Plc Simon Baker - Redburn Atlantic Manos Mastorakis - Deutsche Bank Jay Olson - Oppenheimer Operator Welcome to BioNTech's Third Quarter 2024 Earnings Call. I would like to hand the call over to Michael Horowicz, Director of Investor Relations.

BioNTech surprises with Q3 profit driven by strong vaccine sales
proactiveinvestors.com04 November 2024 Sentiment: POSITIVE

BioNTech SE reported a surprising profit for the third quarter, achieving earnings of €0.81 ($0.88) per diluted share, far exceeding analyst expectations of a loss of €1.84. The Mainz, Germany-based company also posted sales of €1.2 billion, nearly three times higher than anticipated.

BioNTech Announces Third Quarter 2024 Financial Results and Corporate Update
globenewswire.com04 November 2024 Sentiment: POSITIVE

Conference call and webcast scheduled for November 4, 2024, at 8:00 a.m. EST (2:00 p.m. CET)

BioNTech to Host Innovation Series R&D Day on November 14, 2024
globenewswire.com31 October 2024 Sentiment: POSITIVE

MAINZ, Germany, October 31 , 2024 (GLOBE NEWSWIRE) --  BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”), will host an edition of the Company's Innovation Series R&D Day at 10:30 a.m. Eastern Standard Time (16:30 p.m. CET) on Thursday, November 14, 2024 in New York City, U.S.

BioNTech to Report Q3 Earnings: Is a Beat in the Cards?
zacks.com25 October 2024 Sentiment: POSITIVE

On BNTX's third-quarter 2024 earnings call, investors' focus is likely to be on the updates related to its oncology pipeline.

BioNTech's Oncology Gamble: High Stakes, Big Potential
seekingalpha.com21 October 2024 Sentiment: POSITIVE

BioNTech's oncology assets, including BNT327/PM8002, show promising results, with a notable 39.3% ORR in PD-L1-negative EGFR-mutated NSCLC patients. BioNTech's stock has risen by 24% since March, outperforming the S&P 500, driven by optimism in their oncology pipeline. Despite a partial FDA hold on BNT316/ONC-392 for NSCLC, other trials and treatments remain unaffected, signaling potential for resolution.

What type of business is BioNTech SE?

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A, as well as strategic partnership the Coalition for Epidemic Preparedness Innovations (CEPI) to strengthen africa's mrna vaccine ecosystem. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

What sector is BioNTech SE in?

BioNTech SE is in the Healthcare sector

What industry is BioNTech SE in?

BioNTech SE is in the Biotechnology industry

What country is BioNTech SE from?

BioNTech SE is headquartered in Germany

When did BioNTech SE go public?

BioNTech SE initial public offering (IPO) was on 10 October 2019

What is BioNTech SE website?

https://www.biontech.de

Is BioNTech SE in the S&P 500?

No, BioNTech SE is not included in the S&P 500 index

Is BioNTech SE in the NASDAQ 100?

No, BioNTech SE is not included in the NASDAQ 100 index

Is BioNTech SE in the Dow Jones?

No, BioNTech SE is not included in the Dow Jones index

When was BioNTech SE the previous earnings report?

No data

When does BioNTech SE earnings report?

The next expected earnings date for BioNTech SE is 20 March 2025